Potential common mechanism of four Chinese patent medicines recommended by diagnosis and treatment protocol for COVID-19 in medical observation period

Lin Wang1*, Zheyi Wang2†, Zhihua Yang3, Xingwang Wang4, Liping Yan5, Jianxiong Wu6, Yue Liu1, Baohui Fu1 and Hongtao Yang1*

1Department of Nephrology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China, 2Qilu Hospital, Shandong University, Shandong, China, 3Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China, 4College of Animal Science and National Engineering Research Center for Breeding Swine Industry, South China Agricultural University, Guangzhou, Guangdong, China, 5School of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang, China

The global epidemic has been controlled to some extent, while sporadic outbreaks still occur in some places. It is essential to summarize the successful experience and promote the development of new drugs. This study aimed to explore the common mechanism of action of the four Chinese patent medicine (CPMs) recommended in the Medical Observation Period COVID-19 Diagnostic and Treatment Protocol and to accelerate the new drug development process. Firstly, the active ingredients and targets of the four CPMs were obtained by the Chinese medicine composition database (TCMSP, TCMID) and related literature, and the common action targets of the four TCMs were sorted out. Secondly, the targets of COVID-19 were obtained through the gene-disease database (GeneCards, NCBI). Then the Venn diagram was used to intersect the common drug targets with the disease targets. 397 GO biological functions and 166 KEGG signaling pathways were obtained. The former was mainly enriched in regulating apoptosis, inflammatory response, and T cell activation.
The latter, with 92 entries related to COVID-19, was mainly enriched to signaling pathways such as Coronavirus disease—COVID-19, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, and Toll-like receptor signaling pathway. Molecular docking results showed that 19/21 of key active ingredients exhibited strong binding activity to recognized COVID-19-related targets (3CL of SARS-CoV-2, ACE2, and S protein), even better than one of these four antiviral drugs. Among them, shinflavanone had better affinity to 3CL, ACE2, and S protein of SARS-CoV-2 than these four antiviral drugs. In summary, the four CPMs may play a role in the treatment of COVID-19 by binding flavonoids such as quercetin, luteolin, and acacetin to target proteins such as ACE2, 3CLpro, and S protein and acting on TNF, IL6, IL1B, CXCL8, and other targets to participate in broad-spectrum antiviral, immunomodulatory and inflammatory responses.

KEYWORDS
COVID-19, Chinese patent medicines, active components, common mechanism of action, network pharmacology, ACE2, 3CL pro

Introduction

Since the beginning of December 2019, COVID-19 has caused devastating consequences (1) and has been declared as the sixth public health emergency of international concern by the World Health Organization (WHO) (2). COVID-19 is highly contagious and spreads quickly, with broader impacts, and the population is generally susceptible (3). In addition, SARS-CoV-2 directly attacks the respiratory system and attacks the respiratory system, but also affects the immune, digestive, cardiovascular, neurological, genitourinary, and other extrapulmonary systems (4, 5). Moreover, related literature reports suggested that patients with COVID-19 might have multiple systemic sequelae during recovery (6). At present, the global epidemic has been controlled to some extent, while sporadic outbreaks still occur in some places. It is essential to summarize the successful experiences of various countries and promote the development of new drugs.

As one of the first countries affected by COVID-19, China has accumulated a lot of valuable experience in fighting COVID-19. It has been shown that Lianhua Qingwen (LHQW), Huoxiang Zhengqi (HXZQ), Jinhua Qinggan (JHQG), and Shufeng Jiedu (SFJD) are effective in treating COVID-19 (7). For COVID-19 patients in the medical observation period, JHQG, LHQW, and SFJD are recommended for fever and fatigue. For fatigue with gastrointestinal discomfort, HXZQ is recommended. In terms of clinical efficacy, in a multi-center randomized controlled study led by academician Nanshan Zhong, a total of 284 patients with COVID-19 were included. The results proved that combining LHQW with conventional treatment can significantly increase the symptom recovery rate, shorten the median time for symptom recovery, and improve the CT and clinical cure rates (8). Ling Chen et al. reviewed the clinical data of 200 patients with ordinary COVID-19 treated at Wuhan Third Hospital from January 27, 2020, to March 5, 2020. The results show that the combined application of SFJD can significantly improve the clinical symptoms of typical COVID-19 patients with cough, sputum, fatigue, chest tightness, and wheezing. The main symptoms are improved. It also can regulate the expression of related peripheral blood inflammation indicators and promote lungs inflammation absorption. At last, the cure rate are improved (9). Academician Boli Zhang and others reviewed 123 patients with mild COVID-19 who were admitted to the emergency department of Hubei Integrated Traditional Chinese and Western Medicine Hospital from February 1 to 5, 2020. The results demonstrated that JHQG combined with conventional western medicine treatment could significantly reduce the clinical symptoms of fever, cough, fatigue, and sputum in patients with mild COVID-19 and relieve anxiety of patients (10). HXZQ is an ancient anti-epidemic prescription. The Diagnosis and Treatment Scheme of Severe Acute Respiratory Syndrome (SARS) (Version 2004) recommends that HXZQ can be used for advanced lung closure, and it has shown initial results in the front line of anti-epidemic (11, 12).

Regarding basic experiments, corresponding evidence can be found for the treatment of COVID-19 by four CPMs. LHQW can work by inhibiting virus replication and reducing the release of cytokines from host cells. The team of academician Nanshan Zhong found in the African green monkey kidney cells Vero E6 cells that LHQW can inhibit the replication of SARS-CoV-2, affect the morphology of the virus, and inhibit pro-inflammatory cytokines at the mRNA level, such as TNF-α, IL-6, CCL2/MCP-1, and CXCL-10/IP-10 (13). SFJD has a broad spectrum of antiviral, anti-inflammatory, and antibacterial effects and can reduce lung injury (14), the levels of
IL-1β and IL-18 in serum and bronchoalveolar perfusion fluid, and the expression levels of NLRP3-related components and virus titers in lung fluid (15ñ17). HXZQ has the functions of antiviral, anti-inflammatory, and immune regulation and could improve gastrointestinal discomfort (18). It can also reduce the inflammatory response in patients with COVID-19 by reducing pro-inflammatory factors, increasing the level of IL-10, and regulating the NF-kB pathway of inflammation (18). JHQG reduces lung inflammation, protects immune organs, regulates cytokine balance, and improves body immunity (19, 20).

Evidence can be discovered in clinical trials and basic experiments for four CPMs to treat COVID-19. Is there a common mechanism of action among them? To promote the development of new drugs and provide a reference for the following basic experiment, we explored the possible mechanism of the action of four CPMs in the treatment of COVID-19 from the perspective of network pharmacology. The workflow is shown in Figure 1.

Materials and methods

Identification of candidate compounds

There were four prescriptions, one from each group. According to the composition of the prescriptions, the traditional Chinese medicine system (TCMSP)1 database was searched for the components of the four prescriptions using the pinyin name or latin name of each herb in each prescription. The composition and dosage of each prescription are shown in Table 1. The herb not found in the TCMSP were supplemented from the TCMID2 database and relevant published literature. The TCMSP database is the most commonly used database for the retrieval of Chinese medicine ingredients and describes the relationships between drugs, targets, and diseases (21, 22). This database includes 500 TCMs from the 2010 edition of the pharmacopeia and 3,069 compounds (23).

ADME screening

Oral bioavailability (OB) refers to the percentage of unmodified drug that is absorbed into the circulatory system after oral administration. The OB is a reliable indicator of the efficacy of oral administration (24). The higher the OB value of the drug is, the greater the clinical value is. After calculation and prediction by of the OBioavail1.1 software, herb components with an OB ≥ 30% were selected as candidate molecules for further analysis in this study (25).

The drug-likeness (DL) refers to the similarity of a compound to a known drug (26). The valuation of the DL coefficient is used in the early stages of drug development to help identify excellent compounds. Therefore, in this study, the tanimoto coefficient (27) was used to evaluate the DL index of the molecule of the four prescriptions. The calculation formula is as follows:

$$T (a, b) = \frac{a^*b}{a^2 + b^2 - ab}$$

where “a” is the molecular property of the herbal compound on the basis of Dragon software3 and “b” is the average molecular property of all the molecules in the DrugBank database.4 The average DL index of all the drugs in this database is 0.18. Therefore, compounds that met the conditions of OB ≥ 30% and DL ≥ 0.18 were defined as active ingredients in this study and were considered to have better pharmacologic effects (29, 30).

Identification of drug targets

In the previous two steps described, we identified the active compounds of the drugs. Then, the corresponding target proteins were identified with the TCMSP and ChemMapper databases, and the repeated targets were simultaneously eliminated. Finally, we used the UniProt KB database5 to standardize the target proteins and identify the confirmed human target genes.

Identification of common targets for four Chinese patent medicine

Jvenn diagrams6 are widely used in biology to illustrate the differences between gene lists originating from different differential analyses (31). The targets of the four prescriptions were intersected, and the selected targets were identified as their common targets by default.

Predicting putative targets of 2019-nCoV

The 2019-nCoV-related target proteins were screened from two databases: (1) the GeneCards (Ver. 4.14)7 database, the largest public platform, is used to effectively navigate gene-disease linkages (32, 33) and (2) the National Center for Biotechnology Information (NCBI)8 database is a popular choice for data deposition (34). We searched the two databases

1 http://tcmspw.com/tcmsp.php, Ver. 2.3.
2 http://119.3.41.228:8000/tcmid/
3 http://www.talete.mi.it/products/dragon_description.htm
4 https://go.drugbank.com/
5 https://www.uniprot.org/
6 http://genoweb.toulouse.inra.fr:8091/app/example.html
7 https://www.genecards.org/
8 https://www.ncbi.nlm.nih.gov/
### TABLE 1  Herb composition of the four prescriptions.

| Prescription name | Latin name/Kewscience website accepted name | Chinese pinyin name | Amount (%) |
|--------------------|---------------------------------------------|---------------------|------------|
| HXZQ               | Pogostemon cablin (Blanco) Benth.           | Guanghuoxiang      | 90 g (15.4%) |
|                    | Atractylodes macrocephala Koidz.           | Baizhu              | 60 g (10.3%) |
|                    | Magnolia officinalis Rehd. et Wils.         | Houpo               | 60 g (10.3%) |
|                    | Pseudostellaria ternata                     | Baxia               | 60 g (10.3%) |
|                    | Perilla frutescens (L.) Britt.              | Zisu                | 30 g (5.1%)  |
|                    | Angelica dahurica (Fisch. ex Hoffm.)Benth. et Hook. f. ex Franch. et Sav | Baizhi | 30 g (5.1%)  |
|                    | Citrus reticulata Blanco                    | Chenpi              | 60 g (10.3%) |
|                    | Poria cocos (Schw.) Wolf                    | Fuling              | 30 g (5.10%) |
|                    | Platycodon grandiflorus (Jacq.) A. DC.     | Jiegeng             | 60 g (10.3%) |
|                    | Glycyrrhiza uralensis Fisch.                | Gancao              | 75 g (12.8%) |
|                    | Areca catechu L.                            | Dafu                 | 30 g (5.10%) |
|                    | Ziziphus jujuba Mill.                      | Dazao               | A jujube     |
|                    | Zingiber officinale Roscoe                 | Shengjiang           |            |

| JHQQ               | Loniceria japonica Thunb                    | Jinynhua            |            |
|                    | Ephedra sinica Stapf                       | Mahuang             |            |
|                    | Gypsum Fibrosum                            | Shigao              |            |
|                    | Prunus armeniaca L.                        | Kuxingren           |            |
|                    | Scutellaria baicalensis Georgi             | Huangqin            |            |
|                    | Forsythia suspensa (Thunb.) Vahl           | Lianqiao            |            |
|                    | Fritillaria thunbergii                     | Zhebeimu            |            |
|                    | Anemarrhena asphodeloides Bunge            | Zhimu               |            |
|                    | Artemisia carvifolia Buch.-Ham. ex Roxb. Hort. Beng.) | Qinbao |            |
|                    | Mentha haplocalyx Briq.                    | Bohe                |            |
|                    | Glycyrrhiza uralensis Fisch.               | Gancao              |            |

| LHQQ               | Forsythia suspensa (Thunb.) Vahl           | Lianqiao            |            |
|                    | Loniceria japonica Thunb                   | Jinynhua            |            |
|                    | Ephedra sinica Stapf                       | Mahuang             |            |
|                    | Prunus armeniaca L.                        | Kuxingren           |            |
|                    | Gypsum Fibrosum                            | Shigao              |            |
|                    | Isatis tinctoria                           | Banlangeng          |            |
|                    | Curtv therea fortunei J. Sm.               | Guanzhong           |            |
|                    | Houttaniya cordata Thunb                   | Yuxingcao           |            |
|                    | Pogostemon cablin (Blanco) Benth.          | Guanghuoxiang       |            |
|                    | Rheum palmatum L.                          | Dahuang             |            |
|                    | Rhodiola rosea L.                          | Hongjingtian        |            |
|                    | Mentha haplocalyx Briq.                    | Bohe                |            |
|                    | Glycyrrhiza uralensis Fisch.               | Gancao              |            |

| SFJD               | Isatis tinctoria                           | Banlangeng          |            |
|                    | Reynouaria japonica Hoatt.                 | Huzhang             |            |
|                    | Forsythia suspensa (Thunb.) Vahl           | Lianqiao            |            |
|                    | Phragmites communis Trin.                  | Lugeng              |            |
|                    | Patrinia scabiosifolia Fisch. ex Trevir.   | Bajiangcao          |            |
|                    | Verbena officinalis L.                     | Mahiancao           |            |
|                    | Bupleurum chinense DC                      | Chaihu              |            |
|                    | Glycyrrhiza uralensis Fisch.               | Gancao              |            |
with the keyword “novel coronavirus” and set the species to “Homo sapiens.”

**Protein–protein interaction network construction and hub gene analysis**

First, we intersected the shared targets of the four prescriptions with the genes associated with 2019-nCoV and obtained a Venn diagram of the intersecting gene symbols.

Then, the potential targets were imported into STRING, which is a database for predicting protein–protein interactions. The STRING database defines PPIs and provides confidence ranges for data scores (high > 0.7; medium > 0.4; low > 0.15) (35). In this study, we limited the species to “Homo sapiens” and selected a confidence score > 0.7. Finally, we exported the downloaded “string_interactions.tsv” file and imported it.

---

9  http://string-db.org/, ver. 11.0.
with GO-BP was enriched via selected (39). In addition, the Hub gene enrichment pathway gene clusters. Relevant pathways with biological term classification and the enrichment analysis of 3.6.3), which is an R package that automates the process of enrichment analyses using the clusterProfiler R package (ver. 3.7.2) software to construct the active ingredient—target—pathway network. At the same time, we constructed the relationship between the common active ingredients of four CPMs.

### Gene ontology and pathway enrichment

Gene Ontology (GO) is an international standard system for classifying gene function (37). GO was used to describe the gene functions and the relationships between these concepts. GO divided gene functions into three aspects: molecular function (MF), cellular component (CC), and biological process (BP) (38).

Kyoto Encyclopedia of Genes and Genomes (KEGG) is a set of artificially drawn pathway maps representing molecular interactions and reaction networks and includes seven major biological processes, including metabolism, cellular processes, organismal systems, and so on.

To further investigate the multiple mechanisms of the potential targets in 2019-ncov, we conducted of GO and KEGG Enrichment analyses using the clusterProfiler R package (ver. 3.6.3), which is an R package that automates the process of biological term classification and the enrichment analysis of gene clusters. Relevant pathways with \( P \)-values < 0.05 were selected (39). In addition, the Hub gene enrichment pathway with GO-BP was enriched via ClueGO.

### Network construction and analysis

To intuitively understand the common mechanism of the four recommended CPMs in the treatment of COVID-19 during the observation period, the identified active components, the potential targets, and the signal pathways with high scores were input into Cytoscape 3.7.2 software to construct the active ingredient—target—pathway network. At the same time, we constructed the relationship between the common active ingredients of four CPMs.

## Molecular docking

Angiotensin-converting enzyme 2 (ACE2) is the entry receptor for 2019-ncov entry into host cells (40); S protein, a type I glycoprotein on the surface of the virus, plays a crucial role during virus entry into the host cells (41); 3-C like protease (3CLpro) play an important role in post-translational processing of replicase polyproteins (42). The crystal structure of the ACE2, S protein, 3CLpro was taken from the RSCB Protein Data Bank (PDB ID: 1R42, 6VSB, 6LUT). PyMol (version 2.3.4) software package was used to erase all the hetero atoms, water molecules, and inhibitor present in the structure (43). the non-covalent interaction of phytochemicals-protease was calculated using autodock Vina (version 1.1.2) software package for the docking analysis (44). Using this method, binding affinities of ligand-protease were determined and reported in kcal/mol unit. For the ACE2, grid box (82 Å × 68 Å × 78 Å) centered at (53.788, 60.568, 30.881) Å, for the 3CLpro, grid box (52 Å × 64 Å × 66 Å) centered at (−26.283, 12.599, 58.965) Å, for the S protein, and grid box (126 Å × 126 Å × 126 Å) centered at (225.616, 226.49, 225.337) Å.

## Molecular dynamics simulation

To further investigate the stability of ligand small molecule binding proteins, molecular dynamics simulations (MDS) were performed using Gromacs 2020.6 software. Because the small ligand molecule is a multi-carbon ring skeleton structure, the Charmm36 force field with the TIP3P water model was chosen for simulation (see Supplementary Data Sheet 1 for specific parameters). The system temperature was set to 37°C for sodium chloride solution to simulate the real environment in the human body. During the MD simulation, all hydrogen bonds involved were constrained using the LINCS algorithm with an integration step of 2 fs. The electrostatic interactions were calculated using the Particle-mesh Ewald (PME) method with the cut-off value set to 1.2 nm. The non-key interaction truncation value is set to 10 Å and is updated every 10 steps. The protein-ligand complexes (hereafter referred to as complexes) are first pre-equilibrated for 100 ps to optimize the initial conformation of the protein in the solvent. After that, the NVT equilibrium of 100 ps with a coupling time constant of 0.1 ps was performed using a modified Berendsen temperature coupling algorithm to warm up the

### Table 2

| Prescription name | Number of compounds | Number of active ingredients | Number of predicted targets |
|------------------|---------------------|-----------------------------|-----------------------------|
| HXZQ             | 1,848               | 203                         | 269                         |
| JHQG             | 1,818               | 228                         | 286                         |
| LHQW             | 1,773               | 241                         | 246                         |
| SFJD             | 1,151               | 179                         | 259                         |

Text references:

10 www.cytoscape.org/
11 http://apps.cytoscape.org/apps/cytohubba
complex to 310 K with the solvent system. Subsequently, a 100 ps NPT equilibration was performed using a Berendsen constant pressure to equilibrate the solvent to the complex system to 1 bar. Ultimately, MDS of 50 ns duration was conducted to further investigate ligand binding relative to the receptor. Root Mean Square Deviation (RMSD) analysis was performed on the simulation results to analyze the stability of the ligand relative to the receptor during the simulation. The radius of gyration (Rg) can characterize the tightness of the protein structure and likewise relies on the radius of gyration to indicate the changes in the peptide chain relaxation of the protein during the simulation. In addition, hydrogen bond number analysis was performed for ligand and receptor binding to observe whether the binding is stable from the bonding perspective.

Results

The compounds, active ingredients and related targets of the four prescriptions

Based on the TCMSP database and the existing literature reports, 1,848, 1,818, 1,773, and 1,151 compounds
FIGURE 3
Mapping relationships between the four recommended CPMs and COVID-19. (A) Intersection targets of COVID-19 and four CPMs. (B) Protein interactions among 51 potential targets. The node’s size indicates the target’s degree, and the larger the node is, the higher the importance is. The thicker edges suggest stronger interactions. The degree value of nodes is positively correlated with node size and color brightness. The middle 10 targets are Hub genes screened based on the MCC method.

FIGURE 4
The hub genes were screened based on MCODE.
TABLE 3 The 11 hub nodes and their topological properties.

| Rank | Name | Degree | Betweenness centrality | Closeness centrality | MCC score |
|------|------|--------|------------------------|----------------------|-----------|
| 1    | TNF  | 33     | 0.046                  | 0.77                 | 2.02E + 07 |
| 2    | IL6  | 34     | 0.061                  | 0.783                | 2.02E + 07 |
| 3    | IL1B | 29     | 0.051                  | 0.712                | 1.76E + 07 |
| 4    | CXCL8| 24     | 0.026                  | 0.662                | 1.64E + 07 |
| 5    | CCL2 | 24     | 0.023                  | 0.671                | 1.56E + 07 |
| 6    | IL2  | 21     | 0.013                  | 0.644                | 1.51E + 07 |
| 7    | IL4  | 19     | 0.005                  | 0.603                | 1.39E + 07 |
| 8    | ICAM1| 22     | 0.021                  | 0.653                | 1.19E + 07 |
| 9    | IFNG | 18     | 0.011                  | 0.573                | 1.14E + 07 |
| 10   | IL10 | 22     | 0.012                  | 0.635                | 1.08E + 07 |
| 11   | MCL1 | 11     | 0.002                  | 0.547                |           |

of the four prescriptions HXZQ, JHQG, LHQW, and SFJD were retrieved, respectively. According to the criteria of OB ≥ 30% and DL ≥ 0.18, 203, 228, 241, and 179 active compounds and 269, 286, 246, and 259 predicted targets were identified, respectively. The number of the components, active components and potential targets of each prescription is shown in Table 2.

Common targets for four prescriptions

A total of 233 common targets of the four prescriptions were identified through jvenn diagrams, as shown in Figure 2.

Protein–protein interaction network and hub gene analysis

2019-nCoV gene dataset collection from the NCBI and GeneCards databases, 48 potential targets and 350 potential targets in 2019-nCoV were identified, respectively, and 46 duplicates were eliminated. A total of 352 targets related to 2019-nCoV were identified.

Among the above 352 2019-nCoV-related targets, the four prescriptions shared 51 common targets with the targets in 2019-nCoV (Figure 3). The 51 putative therapeutic targets were imported into the STRING database to establish the putative therapeutic target PPI network, and then the “string_interaction.tsv” file was imported into Cytoscape 3.7.2 to perform network analysis. The screening of hub genes was performed using Cytoscape’s plugin cytoHubba and MCODE, respectively. The results of both screens were combined, and a total of 11 hub genes were obtained, namely TNF, IL6, IL1B, CXCL8, CCL2, IL2, IL4, ICAM1, IFNG, IL10, and MCL1. The hub genes screened by the plug-in cytoHubba and the plug-in MCODE are shown in Figures 3B, 4, respectively. The topological parameters of the 11 hub genes are shown in Table 3.

Pathway and gene ontology term enrichment analysis

Gene ontology enrichment

A total of 396 GO-BPs, 55 GO-MFs, and 33 GO-CCs were enriched by R package (version 3.6.3). The top 20 GO terms according to P-values < 0.05 are shown in Figure 5. BP was mainly enriched in the regulation of the apoptosis process (5 in total), response to oxidative stress (3 in total), response to lipopolysaccharide (2 in total), response to molecules of bacterial origin (2 in total), inflammatory response, T cell activation and so on (see Figure 5A for details); CC was mainly concentrated in membrane rafts, membrane microdomains, membrane regions, mitochondrial outer membranes, organelle outer membranes, outer membranes, plasma membrane rafts, RNA polymerase II transcription factor complexes, cell-substrate adherens junctions, cell-substrate junctions and so on, and the membrane had the largest proportion (see Figure 5C); MF was mostly involved in inflammatory mediator cytokines, MAP kinase activity, phosphatase binding, heme binding, and so on (see Figure 5B).

Kyoto encyclopedia of genes and genomes enrichment

To elucidate the signaling pathways involved in the treatment of COVID-19 with four CPMs, we subjected 51 drug and disease intersection targets to pathway enrichment analysis by R 4.1.3. A total of 166 pathways were enriched (P < 0.05), 92 of which may be associated with COVID-19. The first 39 signaling pathways were visualized and analyzed in Figure 6A. Figure 6B shows the enriched signaling pathways hitting hub genes, showing 53 pathways associated with the 11 hub genes. It further indicates that hub genes and enrichment pathways have some credibility. The specific parameters of the hub genes and their associated pathways of the four CPMs are shown in Table 4.
FIGURE 5
GO analysis of 51 potential targets genes. The y-axis shows the name of the GO entry, and the x-axis shows the value of gene number count, the value of which represents the number of targets enriched on the GO entry. The redder the color is, the smaller the value of p. adjust is. (A) The top 20 biological processes (BPs). (B) GO-MF. (C) GO-CC.

FIGURE 6
Pathway enrichment analysis and pathway hit to hub genes. (A) The top 39 signaling pathways associated with 51 potentially acting target genes. Pathways with a P-values < 0.05 were identified. The spot size represents the number of genes, and the color represents the P-value. The horizontal coordinate represents the generation, which is the ratio of the number of intersecting genes enriched in the pathway to the total intersecting genes; the vertical coordinate represents the name of the enriched pathway. (B) Signaling pathways associated with hub genes. The horizontal coordinate represents the number of hub gene hits on the pathway, and the vertical coordinate represents the pathway name.
| KEGG term                                      | Count | %     | Associated genes                                                                 | p-adjust  |
|------------------------------------------------|-------|-------|---------------------------------------------------------------------------------|-----------|
| Cytokine-cytokine receptor interaction          | 9     | 81.82 | TNF, IL6, IL1B, CXCL8, CCL2, IL2, IL4, IFNG, IL10                                | 5.35E-10  |
| IL-17 signaling pathway                         | 7     | 63.64 | TNF, IL6, IL1B, CXCL8, CCL2, IL4, IFNG                                           | 2.23E-21  |
| Influenza A                                     | 7     | 63.64 | TNF, IL6, IL1B, CXCL8, CCL2, IFNG                                               | 1.92E-18  |
| AGE-RAGE signaling pathway in diabetic          | 6     | 54.55 | TNF, IL6, IL1B, CXCL8, CCL2, ICAM1, IFNG                                        | 1.10E-27  |
| complications                                    |       |       |                                                                                 |           |
| Coronavirus disease—COVID-19                    | 6     | 54.55 | TNF, IL6, IL1B, CXCL8, CCL2, IL2                                               | 1.83E-12  |
| Lipid and atherosclerosis                       | 6     | 54.55 | TNF, IL6, IL1B, CXCL8, CCL2, ICAM1, IFNG                                      | 2.47E-23  |
| Viral protein interaction with cytokine and      | 6     | 54.55 | TNF, IL6, CXCL8, CCL2, IL2, IL10                                               | 2.58E-08  |
| cytokine receptor                               |       |       |                                                                                 |           |
| JAK-STAT signaling pathway                      | 6     | 54.55 | IL6, IL2, IL4, IFNG, IL10, MCL1                                               | 1.31E-06  |
| C-type lectin receptor signaling pathway        | 5     | 45.45 | TNF, IL6, IL1B, IL2, IL10                                                        | 9.90E-15  |
| Fluid shear stress and atherosclerosis          | 5     | 45.45 | TNF, IL1B, CCL2, ICAM1, IFNG                                                    | 4.87E-13  |
| Herpes simplex virus 1 infection                | 5     | 45.45 | TNF, IL6, IL1B, CCL2, IFNG                                                      | 2.48E-06  |
| Human cytomegalovirus infection                 | 5     | 45.45 | TNF, IL6, IL1B, CXCL8, CCL2                                                     | 5.48E-15  |
| NOD-like receptor signaling pathway             | 5     | 45.45 | TNF, IL6, IL1B, CXCL8, CCL2                                                     | 1.09E-12  |
| T cell receptor signaling pathway               | 5     | 45.45 | TNF, IL2, IL4, IFNG, IL10                                                       | 2.97E-13  |
| Th1 cell differentiation                        | 5     | 45.45 | IL6, IL2, IL2, IL4, IFNG                                                         | 4.44E-13  |
| TNF signaling pathway                           | 5     | 45.45 | TNF, IL6, IL1B, CXCL8, ICAM1                                                    | 1.13E-18  |
| Hematopoietic cell lineage                      | 4     | 36.36 | TNF, IL6, IL1B, IL4                                                             | 0.000561  |
| Human T-cell leukemia virus 1 infection         | 4     | 36.36 | TNF, IL6, IL2, ICAM1                                                            | 1.23E-11  |
| Intestinal immune network for IgA production   | 4     | 36.36 | IL6, IL2, IL4, IL10                                                             | 1.23E-06  |
| NF-kappa B signaling pathway                    | 4     | 36.36 | TNF, IL6, CXCL8, ICAM1                                                          | 1.10E-10  |
| PI3K-Akt signaling pathway                      | 4     | 36.36 | IL6, IL2, IL4, MCL1                                                             | 5.77E-09  |
| Toll-like receptor signaling pathway            | 4     | 36.36 | TNF, IL6, IL1B, CXCL8                                                           | 9.90E-15  |
| Antifolate resistance                           | 3     | 27.27 | TNF, IL6, IL1B                                                                  | 6.27E-05  |
| Autoimmune thyroid disease                      | 3     | 27.27 | IL2, IL4, IL10                                                                  | 0.00052   |
| Epstein-Barr virus infection                    | 3     | 27.27 | TNF, IL6, ICAM1                                                                 | 3.49E-12  |
| Hepatitis B                                     | 3     | 27.27 | TNF, IL6, CXCL8                                                                 | 3.28E-20  |
| Kaposis sarcoma-associated herpesvirus infection| 3     | 27.27 | IL6, CXCL8, ICAM1                                                               | 1.66E-17  |
| Natural killer cell mediated cytotoxicity        | 3     | 27.27 | TNF, ICAM1, IFNG                                                               | 2.76E-06  |
| Necroptosis                                     | 3     | 27.27 | TNF, IL2, IFNG                                                                  | 1.15E-06  |
| Prion disease                                   | 3     | 27.27 | TNF, IL6, IL1B                                                                  | 1.92E-07  |
| Th1 and Th2 cell differentiation                | 3     | 27.27 | IL2, IL4, IFNG                                                                  | 6.18E-10  |
| Apoptosis                                       | 2     | 18.18 | TNF, MCL1                                                                       | 3.94E-13  |
| Chemokine signaling pathway                     | 2     | 18.18 | CXCL8, CCL2                                                                    | 4.46E-09  |
| Cytosolic DNA-sensing pathway                   | 2     | 18.18 | IL6, IL1B                                                                       | 0.000957  |
| Fc epsilon RI signaling pathway                 | 2     | 18.18 | TNF, IL4                                                                       | 4.67E-07  |
| FoxO signaling pathway                          | 2     | 18.18 | IL6, IL10                                                                       | 2.76E-06  |
| Hepatitis C                                     | 2     | 18.18 | TNF, IFNG                                                                       | 2.04E-12  |
| HIF-1 signaling pathway                         | 2     | 18.18 | IL6, IFNG                                                                       | 8.80E-12  |
| Insulin resistance                              | 2     | 18.18 | TNF, IL6                                                                       | 9.28E-05  |
| MAPK signaling pathway                          | 2     | 18.18 | TNF, IL1B                                                                       | 5.20E-10  |
| RIG-I-like receptor signaling pathway           | 2     | 18.18 | TNF, CXCL8                                                                     | 5.56E-07  |
| TGF-beta signaling pathway                      | 2     | 18.18 | TNF, IFNG                                                                       | 0.000463  |
| Adipocytokine signaling pathway                 | 1     | 9.09  | TNF                                                                            | 0.0121    |
| EGFR tyrosine kinase inhibitor resistance       | 1     | 9.09  | IL6                                                                            | 3.41E-09  |
| Human immunodeficiency virus 1 infection        | 1     | 9.09  | TNF                                                                            | 6.67E-12  |
| Human papillomavirus infection                  | 1     | 9.09  | TNF                                                                            | 2.27E-08  |
| Inflammatory mediator regulation of TRP channels| 1     | 9.09  | IL1B                                                                           | 0.00054   |

(Continued)
TABLE 4 (Continued)

| KEGG term                        | Count | %     | Associated genes | p-adjust |
|----------------------------------|-------|-------|------------------|----------|
| Leukocyte transendothelial migration | 1     | 9.09  | ICAM1            | 0.007382 |
| mTOR signaling pathway           | 1     | 9.09  | TNF              | 0.00387  |
| Phospholipase D signaling pathway| 1     | 9.09  | CXCL8            | 0.003141 |
| Sphingolipid signaling pathway   | 1     | 9.09  | TNF              | 2.41E-11 |
| Viral myocarditis                | 1     | 9.09  | ICAM1            | 0.0008   |

As shown in Table 5, the pathways were mainly enriched in three areas: (i) viral infections, such as coronavirus disease—COVID-19, and human cytomegalovirus infection. (ii) immunity, such as Toll-like receptor signaling pathway, T cell receptor signaling pathway, NOD-like receptor signaling pathway, and other signaling pathways; (iii) inflammation, such as cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, C-type lectin receptor signaling pathway, etc. In addition, the relationship between the Hub gene enrichment pathway and the gene ontology biological process (GO-BP) is shown in Figure 7. As shown in Figure 7, the pathways enriched by the hub genes, such as coronavirus disease, cytokine-cytokine receptor interaction, and viral protein interaction with cytokine and cytokine receptor, are closely related to the production and regulation of molecular mediators of the immune response, the positive regulation of immune effector processes, and the regulation of leukocyte migration.

Network construction and analysis

Active component-common active component network of four prescriptions

There are 411 nodes and 850 edges in the active component-common active component network of the four prescriptions (Figure 8). The details of the 101 common active components are provided in Supplementary Table 1.

Active component-potential target–pathway network

The 53 signaling pathways associated with hub genes, potential targets, and active ingredients in the signaling pathways were entered into Cytoscape 3.7.2 software to construct the active ingredient-potential target-pathway network, as shown in Figure 9. According to the network diagram and topological parameters, it can be seen that the 21 active ingredients, 46 targets, and 56 signaling pathways are closely related to each other. The greater the nodal degree, the more biological functions it involves, indicating its biological importance. On the one hand, considering that fewer key components were screened by degree greater than the mean value, and on the other hand, we screened the pathway three times to further ensure the integrity and reliability of the study, all the active ingredients enriched this time were initially used as key active ingredients. Subsequently, key components of the initial screen were excluded if they had docking binding energies greater than −5 kcal/mol to the three potential action targets of COVID-19. Twenty-one key compounds were finally identified, and their specific parameters and sources are shown in Table 6.

Molecular docking

Lopinavir, remdesivir, ritonavir, ribavirin have been widely used in antiviral therapy (45ñ47), mainly through the control of their binding sites. In Autodock Vina scoring system, lower binding score indicates the better docking interaction between ligand and protein. According to the analysis of docking results (Table 7), binding affinities of the phytochemicals are distributed within the range of −7.0 to −9.1 kcal/mol. Similar to anti-viral drugs within the range of −6.1 to −10.4 kcal/mol. Molecular docking is performed to find out the best candidates among the 9 phytochemicals based on their binding scores. In docking with 3CLPro, ACE2, and S protein, the affinity of shinflavanone was in the order of −8.4, −9.7, and −10.4 kcal/mol, which were
superior to these four antiviral drugs. In addition, the beta-carotene binding energy in docking with ACE2 was lower than that of Ritonavir and Ribavirin. In docking with S protein, beta-carotene and beta-sitosterol binding energy were lower than Remdesivir, Ribavirin, and Ritonavir; hyperforin and baicalein binding energy was lower than Ribavirin and Ritonavir.

Additionally, the docking analysis between the selected compounds and the target proteins was shown in Figure 10. In docking with 3CLPro, the compound shinflavanone formed hydrogen bonds with GLY-143 to interact with each other (Figure 10A). In docking with S proteins, β-sitosterol formed three hydrogen bonds with ARG-1039 (A), ARG-1039 (B), and ARG-1039 (C), respectively (Figure 10F). Hyperforin forms two hydrogen bonds with LEU-1024 (B) and THR-1027 (B), respectively (Figure 10G). Baicalein formed two hydrogen bonds with GLN-1036(C) and HIS-1048(C), respectively (Figure 10H). These 21 phytochemicals bind to the active site of the major protease of 2019-nCOV with lower binding energy than the crystal structured ligand, implying that they may have strong antiviral activity.

**Molecular dynamics simulation**

From the RMSD plot analysis (Figure 11A), it is observed that the complex formed by the compound and ACE2 protein was more stable during the simulated 50 ns. The RMSD values of the ligand relative to the receptor were maintained in a low range and fluctuated less, suggesting that the ligand did not move much relative to the receptor and the binding was more stable. The RMSD of the compound relative to 3-C like protease maintained an increasing trend in the first 25 ns or so, and showed a trend of decreasing and then increasing to the RMSD value at 25 ns from 25 to 40 ns, and basically maintained equilibrium with less fluctuation in the last 10 ns. The possible reason was that the ligand shifted the binding cavity of the protein as the simulation proceeded. After entering the new binding cavity and undergoing particular rotation, it maintained a stable conformation and conformation in the...
last 10 ns, forming a more stable binding. The stability of the binding can be further verified by extending the duration of the kinetic simulation later. The RMSD values of the compounds relative to the S proteins kept fluctuating widely during the simulation, suggesting that the binding between the ligand and the receptor may not be very stable. Therefore, further extension of the kinetic time is needed to investigate the binding stability.

Rg can characterize the tightness of the protein structure, and the same radius of gyration can be relied on to distinguish the changes in the peptide chain relaxation of the protein during the simulation. As shown in Figure 11C, the Rg of both 3CLpro and ACE2 proteins remained relatively stable throughout the simulation. The Rg of 3CLpro protein was basically maintained around 2.25 nm, and that of ACE2 protein was basically maintained around 2.5 nm, suggesting that the complexes formed by the proteins and ligands were more stable. However, the Rg of S protein shows some fluctuations, which may be related to the fact that the small molecule is constantly undergoing conformational and conformational transitions, which in turn have some effects on the protein structure. It is in agreement with the previous analysis of RMSD and RMSF.

The number of hydrogen bonds between the protein and the ligand varies with time during the simulated 50 ns. As can be seen in Figure 11B, the 3-C like protease maintains the formation of more than two hydrogen bonds between the ligand and the receptor for nearly half of the simulation. Several hydrogen bonds between the ACE2 protein and the ligand were always formed. The overall situation was similar to that of 3-C like protease. The S protein basically maintains a hydrogen bond with the ligand during the simulation, suggesting that the ligand may always keep a part of the molecule relatively static in conformation and conformation during the simulation. In contrast, the rest of the molecule undergoes conformational and conformational transitions.

In general, the ligand maintains a more stable binding to the 3-C like protease and ACE2 protein throughout the simulation.
FIGURE 9
Potential active component–potential target–pathway network. Green circles represent action targets, yellow triangles represent the 53 signaling pathways associated with Hub genes, and rosy V shapes represent the four prescribed active ingredients. The node size is positively related to the degree, and the edges represent the interactions between the nodes.

In the complexes formed with S proteins, the ligands kept undergoing conformational and conformational transitions. The stability of S protein-ligand binding can be further explored later by extending the kinetic simulation time.

Discussion

Traditional Chinese medicine (TCM) and herbal medicines (HMs) have a long history and play an indispensable role in the prevention and treatment of several epidemic diseases (48). Based on network pharmacology and systems biology, this paper discusses the possible common mechanisms of the four CPMs recommended by the Diagnosis and Treatment Protocol for COVID-19 during the Medical Observation period.

The material basis of the medicinal effect of traditional Chinese medicine

These four CPMs have been widely used and well-established in the Chinese protocol for treating COVID-19. At the same time, the specific content and proportion of the ancient books from which the CPM is derived are described for convenience of reference. The research on the material basis of the efficacy of TCM is gradually rising from molecular biology to the level of systems biology. Although there is no clear definition of the material basis of pharmacological efficacy in Chinese medicine, different theories and hypotheses exist, such as the all-component theory, the active ingredient theory, the metabolic component, and the multi-component synergism theory (49). However, most scholars believe that TCM’s effectiveness is reflected in the
Table 6: Pharmacokinetics and sources of the top 21 key active ingredients.

| Mol ID     | Molecule name                                                                 | Degree | OB (%) | DL  | Source (abbreviations of Latin names) |
|------------|-------------------------------------------------------------------------------|--------|--------|-----|---------------------------------------|
| MOL00098   | Quercetin                                                                     | 10     | 46.43  | 0.28| PC, GU, ZJ, LJ, ES, FS, AC, HC, RJ, Patriniaceae, VO, BC, RR, FT |
| MOL0006    | Luteolin                                                                      | 7      | 36.16  | 0.25| PF, PG, LJ, ES, FS, AC, MH, RJ, Patriniaceae, VO, RR, GU |
| MOL01689   | Acacetin                                                                       | 5      | 34.97  | 0.24| PG, SB, MH, IT, Patriniaceae |
| MOL00471   | Aloe-emodin                                                                   | 3      | 83.38  | 0.24| MH, RP |
| MOL00422   | Kaempferol                                                                    | 2      | 41.88  | 0.24| GU, FS, AA, AI, AC, LJ, FS, ES, CF, HC, Patriniaceae, VO, BC, RR, FT |
| MOL03283   | (2R, 3R, 4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethyl-tetralin-6-ol| 2      | 66.51  | 0.39| FS |
| MOL04328   | Naringenin                                                                    | 2      | 59.29  | 0.21| GU, CR, MH, GU, ES |
| MOL05916   | Isorhamnetin                                                                  | 1      | 37.78  | 0.3 | PC |
| MOL00358   | Beta-sitosterol                                                                | 1      | 36.91  | 0.75| PT, PF, ZJ, ZO, SB, FS, FT, AI, LJ, ES, RP, RJ, Patriniaceae, VO |
| MOL007424  | Artemisin                                                                       | 1      | 49.88  | 0.31| AC |
| MOL03347   | Hyperforin                                                                     | 1      | 44.03  | 0.6 | FS |
| MOL00096   | (−)-catechin                                                                   | 1      | 49.68  | 0.24| ZJ, Rheum |
| MOL002714  | Baicalein                                                                      | 1      | 33.52  | 0.21| PT, SB, GU |
| MOL003006  | (−)-(3R,8S,9R,9aS,10aS)-9-ethenyl-8-(beta-D-glucopyranoxyloxy)-2,3,9,9a,10a-hexahydro-5-oxo-5H,8H-pyrazolo[4,3-d]oxazolo[3,2-a]pyridine-3-carboxylic acid,qt | 1      | 87.47  | 0.23| LJ |
| MOL00392   | Formononetin                                                                   | 1      | 69.67  | 0.21| GU |
| MOL00497   | Licochalcone a                                                                 | 1      | 40.79  | 0.29| GU, PC |
| MOL01736   | (−)-taxifolin                                                                  | 1      | 60.51  | 0.27| Isatis |
| MOL02773   | Beta-carotene                                                                  | 1      | 37.18  | 0.58| PF, ZJ, LJ, AL, LJ, VO |
| MOL04895   | Shinflavanone                                                                  | 1      | 31.79  | 0.72| GU |
| caso4 2h2o | Caso4 2h2o                                                                    | 1      | /      | /   | GF |
| MOL00492   | (+)-catechin                                                                   | 1      | 54.83  | 0.24| PF, ZJ, ES, PA, ES, PA, RJ |

The Latin names of the four PCM constituent drugs can be referred to as shown in Table 1.

Overall biological effect of the entire chemical composition, which is the synergistic effect of multiple components, not a single chemical entity. It is because a single ingredient does not represent an herb’s drug properties and efficacy, nor is the efficacy the sum of all ingredients (50). In drug compatibility, there will be physical or chemical reactions, which will lead to the formation of new compounds, affect the dissolution rate of effective and toxic components in the formula, or have no noticeable effect. In addition, the chemical components that act on multiple targets and produce overall effects after entering the human body may originate from inherent components of the herbs, products formed during the preparation process, or metabolites produced by the interaction between the drug and the body after entering the body (51). Lan Wang et al. demonstrated synergistic effects between three active compounds isolated from three components of a TCM formulation in an animal model of acute promyelocytic leukemia (APL) and an APL cell line (52). At present, the existing methods to study the synergistic effect of Chinese herbal medicines include mathematical modeling (such as CI) and computer technology (such as systems biology analysis, S2S), fractionation technology combined with CI models, and combination of effective components of traditional Chinese medicines (50). In addition, in 2008, China launched the 15-year “Herbalome Project,” which aims to elucidate the chemical composition, structure, and function of commonly used Chinese herbal medicines and Chinese medicine formulations, establish a standard resource library and explain the synergistic and complementary mechanisms of multi-component Chinese medicines at multiple targets (53, 54). Although the synergistic research of Chinese herbal medicine is still in its infancy, we believe that it will develop better and better with the efforts of everyone.
| Compounds                        | Structure                                                                 | CAS ID   | MF    | MW    | Affinity/ (kcal/mol) | Affinity/ (kj/mol) |
|---------------------------------|---------------------------------------------------------------------------|----------|-------|-------|----------------------|-------------------|
| Quercetin                       | ![Quercetin Structure](image)                                             | 117-39-5 | C15H10O7 | 302.24 | -7.4                 | -30.932           |
|                                 |                                                                           |          |       |       | -8                   | -33.440           |
|                                 |                                                                           |          |       |       | -8.2                 | -34.276           |
| Luteolin                        | ![Luteolin Structure](image)                                             | 491-70-3 | C15H10O6 | 286.24 | -7.3                 | -30.514           |
|                                 |                                                                           |          |       |       | -8                   | -33.440           |
|                                 |                                                                           |          |       |       | -8.3                 | -34.694           |
| Acacetin                        | ![Acacetin Structure](image)                                             | 480-44-4 | C16H12O5 | 284.26 | -7.3                 | -30.514           |
|                                 |                                                                           |          |       |       | -7.6                 | -31.768           |
|                                 |                                                                           |          |       |       | -7.7                 | -32.186           |
| Aloe-emodin                     | ![Aloe-emodin Structure](image)                                          | 481-72-1 | C15H10O5 | 270.24 | -7.4                 | -30.921           |
|                                 |                                                                           |          |       |       | -7.8                 | -32.604           |
|                                 |                                                                           |          |       |       | -8                   | -33.440           |
| Kaempferol                      | ![Kaempferol Structure](image)                                           | 520-18-3 | C15H10O6 | 286.25 | -7.8                 | -32.604           |
|                                 |                                                                           |          |       |       | -7.6                 | -31.768           |
|                                 |                                                                           |          |       |       | -8.1                 | -33.858           |
| (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethyl-tetralin-6-ol | ![Structure](image)                                                      | 548-29-8 | C20H12O6 | 360.4  | -6.2                 | -25.916           |
|                                 |                                                                           |          |       |       | -7.3                 | -30.514           |
|                                 |                                                                           |          |       |       | -8                   | -33.440           |
| Naringenin                      | ![Naringenin Structure](image)                                           | 67604-48-2 | C15H12O5 | 272.25 | -7.1                 | -29.678           |
|                                 |                                                                           |          |       |       | -8.2                 | -34.276           |
|                                 |                                                                           |          |       |       | -8.3                 | -34.694           |
| Irisolidone                     | ![Irisolidone Structure](image)                                          | 2345-17-7 | C17H14O6 | 314.29 | -7.4                 | -30.932           |
|                                 |                                                                           |          |       |       | -6.9                 | -28.842           |
|                                 |                                                                           |          |       |       | -7.4                 | -30.932           |
| Beta-sitosterol                 | ![Beta-sitosterol Structure](image)                                       | 83-46-5 | C29H50O | 414.71 | -7.5                 | -31.356           |
|                                 |                                                                           |          |       |       | -7.8                 | -32.604           |
|                                 |                                                                           |          |       |       | -9.1                 | -38.038           |

(Continued)
| Compounds | Structure | CAS ID | MF     | MW     | Affinity/ (kcal/mol) | Affinity/ (kJ/mol) |
|-----------|-----------|--------|--------|--------|---------------------|--------------------|
| Artemisinin | ![Structure](image) | 63968-64-9 | C15H22O5 | 282.33 | −7.2 | −30.096<sup>3</sup> |
|           |           |        |        |        | −7.2 | −30.096<sup>3</sup> |
|           |           |        |        |        | −8.4 | −35.112<sup>3</sup> |
| hyperforin | ![Structure](image) | 11079-53-1 | C35H52O4 | 536.8 | −6.1 | −25.498<sup>3</sup> |
|           |           |        |        |        | −7.7 | −32.186<sup>3</sup> |
|           |           |        |        |        | −8.6 | −35.948<sup>3</sup> |
| (−)-catechin | ![Structure](image) | 18829-70-4 | C15H14O6 | 290.27 | −7.3 | −30.514<sup>3</sup> |
|           |           |        |        |        | −7.7 | −32.186<sup>3</sup> |
|           |           |        |        |        | −8.3 | −35.300<sup>3</sup> |
| Baicalein | ![Structure](image) | 491-67-8 | C15H10O5 | 270.23 | −7.7 | −32.186<sup>3</sup> |
|           |           |        |        |        | −7.8 | −32.604<sup>3</sup> |
|           |           |        |        |        | −8.5 | −35.530<sup>3</sup> |
| MOL003006 | ![Structure](image) |        |        | 281.29 | −6.5 | −27.17<sup>2</sup> |
|           |           |        |        |        | −6.7 | −28.006<sup>3</sup> |
|           |           |        |        |        | −7.5 | −31.352<sup>2</sup> |
| Formononetin | ![Structure](image) | 485-72-3 | C16H12O4 | 268.26 | −7.2 | −30.096<sup>3</sup> |
|           |           |        |        |        | −7.4 | −30.932<sup>3</sup> |
|           |           |        |        |        | −7.5 | −31.352<sup>2</sup> |
| Licochalcone a | ![Structure](image) | 58749-22-7 | C21H22O4 | 338.4 | −7.4 | −30.932<sup>3</sup> |
|           |           |        |        |        | −8.0 | −33.440<sup>3</sup> |
|           |           |        |        |        | −7.7 | −32.186<sup>3</sup> |
| (−)-taxifolin | ![Structure](image) | 111003-33-9 | C15H12O7 | 304.25 | −7.4 | −30.932<sup>3</sup> |
|           |           |        |        |        | −7.7 | −32.186<sup>3</sup> |
|           |           |        |        |        | −7.9 | −33.028<sup>3</sup> |
| Beta-carotene | ![Structure](image) | 7235–40–7 | C40H56 | 536.9 | −7.5 | −31.352<sup>2</sup> |
|           |           |        |        |        | −7.8 | −32.604<sup>3</sup> |
|           |           |        |        |        | −9.6 | −40.128<sup>3</sup> |

(Continued)
### TABLE 7 (Continued)

| Compounds   | Structure | CAS ID     | MF         | MW       | Affinity/ (kcal/mol) | Affinity/ (kJ/mol) |
|-------------|-----------|------------|------------|----------|----------------------|--------------------|
| Shinflavanone | ![Structure](image1.png) | 157414-03-4 | C25H26O4  | 390.5    | 8.4                  | 35.112             |
|             |           |            |            |          | 9.7                  | 40.546             |
|             |           |            |            |          | 10.4                 | 43.472             |
| (+)-catechin | ![Structure](image2.png) | 154-23-4   | C15H14O6  | 290.27   | 7.1                  | 29.678             |
|             |           |            |            |          | 7.8                  | 32.604             |
|             |           |            |            |          | 8.1                  | 33.858             |
| Remdesivir  | ![Structure](image3.png) | 1809249-37-3 | C27H35N6O8P | 602.58 | 8.2                  | 34.276             |
|             |           |            |            |          | 9                    | 37.620             |
|             |           |            |            |          | 8.7                  | 36.366             |
| Ribavirin   | ![Structure](image4.png) | 36791-04-5 | C8H12N4O5 | 244.2    | 7                    | 29.260             |
|             |           |            |            |          | 7.4                  | 30.932             |
|             |           |            |            |          | 8.4                  | 35.112             |
| Ritonavir   | ![Structure](image5.png) | 155213-67-5 | C37H48N6O5S2 | 720.96 | 7.9                  | 33.022             |
|             |           |            |            |          | 8.5                  | 35.560             |
|             |           |            |            |          | 7.8                  | 32.604             |
| Lopinavir   | ![Structure](image6.png) | 192725-17-0 | C37H48N4O5 | 628.8    | 8.3                  | 34.694             |
|             |           |            |            |          | 9                    | 37.620             |
|             |           |            |            |          | 10                   | 41.800             |

*: Binding energy with 3CL hydrolase; #: Binding energy with ACE2; #: Binding energy to S-protein. MOL003006: (−)-(3R,8S,9R,9aS,10aS)-9-ethenyl-8-(β-D-glucopyranosyloxy)-2,3,9,9a,10,10a-hexahydro-5-oxo-5H,8H-pyrano[4,3-d][oxazole][3,2-a]pyridine-3-carboxylic acid_qt.

### Active compounds analysis

According to the “active ingredient-potential target-pathway,” 21 essential compounds were identified, followed by quercetin, luteolin, acacetin, aloe-emodin, kaempferol, naringenin, irisolidone, beta-sitosterol, artemisinin, hyperforin, etc. Most of them are flavonoids. Flavonoids are natural antiviral compounds with a wide range of antiviral activity, anti-inflammatory, antioxidant, and immunomodulatory effects (55–57). Molecular docking results showed that shinflavanone had a better affinity for SARS-CoV-2 3CL hydrolase, ACE2, and S protein than all four commonly used antiviral drugs, suggesting that it may be superior in interfering with virus entry into host cells and viral replication. In addition, 19 compounds also showed better affinity to SARS-CoV-2 3CL hydrolase or ACE2 or S protein than one of these four commonly used antiviral drugs, such as quercetin, luteolin, acacetin, aloe-emodin, kaempferol, naringenin, beta- sitosterol, artemisinin, hyperforin, baicalein, formononetin, licochalcone A, (−)-taxifolin, beta-carotene, (+)-catechin, irisolidone, and
Flavonoids

Quercetin has many effects, such as anti-inflammatory, immunomodulatory, antioxidant, and free radical scavenging, which can play a prominent therapeutic role in lung injury (58–63). Quercetin can block the enzymatic activity of coronavirus 3cl protease in treating viral infections such as SARS-CoV infection. Quercetin also blocks the entry of the viral receptor complex into the cell and interrupts its life cycle, leading to viral death (64). In addition, as an essential consideration in developing new antiviral drugs (65, 66), quercetin can increase the bioavailability of antiviral drugs in the body. Luteolin has potent anti-inflammatory, antiviral, antibacterial, and other effects (67, 68). At the lowest concentration (1 mol/L), it can effectively reduce the expression of NF-KB P65, IL-1β, IL 6, and TNF-α in anti-inflammatory (69). Kaempferol has antiviral, anti-inflammatory, antioxidant, and other effects (70, 71). In addition, some studies reported that quercetin, luteolin, and kaempferol could inhibit the proteolytic activity of Sars-CoV 3CLpro (52–54). Naringenin is famous for its antiviral effect and has anti-inflammatory, antioxidant, and immunomodulatory effects (72–75). In addition, naringenin can inhibit inflammatory factors through the NF-κB pathway and reduce LPS-induced lung inflammation. Licochalcone A has anti-inflammatory, immune-promoting, and other biological effects (76, 77). It has been reported in the Lancet that the main active ingredient of licorice (glycyrrhizic acid) effectively inhibits the replication of clinical isolates of sars viruses, and licochalcone A may have the same function (78). Shinflavanone is also derived from Glycyrrhiza glabra, and its antiviral may be superior according to molecular docking, but it is relatively little studied at present and needs further research.

Baicalein and acacetin are flavonoids in scutellaria baicalensis, with anti-inflammatory, antioxidant, and ameliorative effects on acute lung injury (79). Baicalein strongly inhibits virus replication and improves the acute lung injury induced by influenza A and B viruses (80). The synergistic activity of baicalein and ribavirin against influenza virus infections in cell culture and mice was investigated by Chen, and it was discovered that, compared with ribavirin alone, the combination of baicalein and ribavirin increased the survival rate in mice infected with a lethal dose of H1N1 influenza virus (81). Furthermore, baicalein and acacetin can significantly reduce airway hyperresponsiveness, inflammation, and mucus production (82, 83). Acacia can resist plasmodium and regulate immunity (84). Most key compounds have antiviral, anti-inflammatory, and immune-regulating effects. Therefore, it can be inferred that they treat 2019-nCoV mainly through anti-inflammatory, antiviral, and immune-regulating activities.

(II). Others

Flavonoids and terpenoids are natural antiviral compounds. Artemisinin is a commonly used anti-malarial terpenoid compound with a broad-spectrum antiviral activity that has recently been repurposed as a potential COVID-19 drug. Recent studies have confirmed the antiviral activity of artemisinin and its derivatives against SARS-2-CoV-2 at micromolar concentrations (85, 86). Several clinical trials have shown that artemisinin-related agents can help improve SARS-CoV-2 clearance, shorten the time to conversion of SARS-CoV-2 tests to negative, improve the patient condition, and contribute to faster recovery of COVID-19 patients (87, 88). In addition, artemisinin has anti-inflammatory activity and reduces systemic levels of inflammatory cytokines that contribute to cytokine storm and inflammatory organ damage in high-risk COVID-19 patients (89). Aloe-emodin can impede coronaviruses’ entry, replication, and release (90–92). In molecular docking, aloe-emodin has an excellent binding ability to the main protease (6LU7) and nucleocapsid phosphoprotein of COVID-19. It can be used as a potential inhibitor of anti-COVID-19 main protease and a potential drug to cure SARS-CoV-2 infection (93, 94).

Target analysis of traditional inhibitors and four Chinese patent medicines

According to the current status of COVID-19 therapy, the targets of COVID-19 inhibitors involve four main areas, which are briefly described as follows.

(1) Antiviral drugs: SARS-CoV-2 main protease inhibitors (95–98), HIV protease inhibitors (99), RNA-dependent RNA polymerase inhibitors (100).

(2) Cytokine monoclonal antibodies/inhibitors: IL6 monoclonal antibodies, complement component 5 inhibitors, PD-1 blocking antibody, human granulocyte-macrophage colony-stimulating factor receptor inhibitors, IL17A antagonist, IL1β antibody, vascular endothelial-derived growth factor antibody, IL1 receptor antagonist, anti-C5a receptor antibody, and tumor necrosis factor-α inhibitor (101).

(3) Interferons: IFN-α1b Eye Drops, IFN-β1b, IFN atomization, IFN-α1b spray, recombinant supercompound IFN, and IFN aerosol inhalation (101).
(4) Others: RAAS inhibitors (102, 103), JAK inhibitors (104), cathepsin L-selective inhibitors, and proton pump inhibitors (105).

At the same time, TCM differs from chemical drugs in that they usually have simple and straightforward targets of action, while CPMs consist of multiple herbs with multiple targets, and their specific targets of action are relatively complex (106). However, the therapeutic targets of the four CPM in the treatment of COVID-19 protocol are consistent with traditional COVID-19 inhibitors, which further confirms its feasibility. The targets of action of four CPMs for the treatment of COVID-19...
are reviewed below. Some of them may still be in the theoretical stage, pending further basic experiments.

1. LHQW

Nanshan Zhong et al. infected Vero-E6 cells and Huh-7 cells with clinically isolated SARS-CoV-2 virus and assessed the antiviral activity of LHQW against SARS-CoV-2 using CPE and plaque reduction assays, and measured the expression levels of pro-inflammatory cytokines in Huh-7 cells by real-time quantitative PCR. The results showed that LHQW significantly inhibited SARS-CoV-2 replication in Vero E6 cells and reduced the production of pro-inflammatory cytokines such as IL-6, TNF-α, CCL-2/MCP-1, and CXCL-10/IP-10 (13).

2. JHQG

JHQG is the first TCM prescription for the treatment of H1N1 infection. Its potential mechanism of action for the treatment of COVID-19 is anti-inflammatory, anti-SARS-CoV-2 (107, 108), mainly through the regulation of interleukin receptors (IL-1A, IL-1B, IL-2, IL-4, IL-6, IL-10), mitogen-activated protein kinase receptors (MAPK1, MAPK3, MAPK8, MAPK14), TNF and other significant targets, thus achieving...
FIGURE 10
Molecular models of the selected compounds binding to the target proteins. (A) The docking mode and interactions between shinflavanone and 3CL. (B–C) Shinflavanone, beta-carotene and ACE2. (D–H) Shinflavanone, beta-carotene, beta_sitosterol, hyperforin, baicalein and S protein.

the treatment of COVID-19 (109–112). JHQG is derived from the combined formula of Yin Qiao San (YQS) and Ma Xing Shi Gan Tang (MXSG) with addition and reduction. Cellular experiments have shown that MXSG can regulate the expression and activation level of the Toll-like receptor (TLR) in the immune response pathway, which regulates the secretion and protein expression of IFN and effectively fights against viruses (113). Animal experiments showed that YQS could antagonize the function of influenza virus non-structural protein NS1, inhibit the expression of the JAK/STAT signaling pathway and promote the production of antiviral protein (Mx A) induced by IFN-α (114).

HXZQ

The potential mechanism of action of HXZQ for COVID-19 is inhibiting SARS-CoV-2 replication, improving immune, and anti-inflammatory, mainly by acting on 3CLpro (115), PTGS2, AR, HSP90AB1, CAMSAP2, PPARG, NOS2, and other targets (116–118).

SFJD

The potential mechanism of action of SFJD for the treatment of COVID-19 is anti-inflammatory, anti-SARS-CoV-2, mainly acting on mitogen-activated protein kinase receptors (MAPK1, MAPK3, MAPK8, MAPK14), interleukin receptors (IL-6, IL-10), TNF, PTGS2, CASP3, and other multiple targets to achieve the therapeutic effect on COVID-19 (119, 120). In SFJD alone or combined with oseltamivir for the treatment of chronic obstructive pulmonary disease induced by influenza A virus, SFJDC alone and combined with oseltamivir were found to control airway inflammation and lung injury in IAV-infected rats by modulating NLRP3 inflammatory vesicles and subsequently downregulating IL-1β and IL-18 (15). The results of experiments in yeast thermogenesis model rats confirmed the significant antipyretic effect of SFJD, which can significantly inhibit the production of inflammatory factors PGE2, thus considerably inhibiting the production of thermogenic cytokines TNF-α, IL-1α, IL-1β, IL-6. It
FIGURE 11
RMSD plot during molecular dynamics simulations. (A) The RMSD of ligand-receptor. (B) The H-Bond of ligand-receptor. (C) The Rg of ligand-receptor. Blue polygonal line means shinflavanone and S protein, red polygonal line means shinflavanone and ACE2, black polygonal line means shinflavanone and 3-C like protease.

FIGURE 12
The specific mechanisms of action of the four CPMs on the Coronavirus disease—COVID-19 pathway. The solid arrows represent activation, the dashed arrows represent indirect effects, and the vertical lines above the arrows represent inhibition.
reduces the amount of thermogenic factors cAMP, Na+, K+-ATPase, decreases cAMP/cGMP, reduces heat production, and increases the amount of endogenous antipyretic mediator AVP, thus exerting its antipyretic effect (121). The immunomodulatory effect of SFID on rats with pneumonia was further verified in a rat model of pneumonia caused by streptococcus pneumonia. It has a therapeutic impact on pneumonia model rats by reducing B lymphocytes, CD8+ ratio, and elevated levels of IL-1α, IL-1β, IL-2, IL-10, TNF-α, IFN-α, IFN-γ, IgM, IgG, CD4+/CD8+, and NK cells (122).

Analysis of the common action targets of four Chinese patent medicines

In the post-genetic era, researchers have recognized that many high-incidence diseases involve multifactorial physiological and pathological factors (123). Multi-target or multi-component therapeutics will receive increasing attention, and traditional Chinese medicine may become an essential resource for multi-component multi-target drug design (124). In this study, a total of 11 hub genes were identified through two plugins in cytoscape, cytoHubba, and Cluego. These hub genes are primarily inflammatory mediator cytokines, which are consistent with four CPM targets, including interleukins (IL-2, IL-4, IL-6, CXCL8, IL-10, and IL-1β), interferon (IFNG), tumor necrosis factor (TNF), chemokine (CCL2), and adhesion molecule (ICAM1). A study published in the Lancet notes that the occurrence and development of 2019-nCoV are closely related to cytokine storms. Cytokine storms are severe systemic reactions caused by the overactivation of the immune system by infection, drugs, or certain diseases, which can lead to multiple organ failure and even death (125). In patients with severe and critical COVID-19, the immune system is disrupted, thereby producing large amounts of inflammatory cytokines, which leads to life-threatening cytokine storms (126). Therefore, it is necessary to detect and interfere with inflammatory cytokines as soon as possible and initiate immunotherapy, aiming to avoid the progression of mild and common infections to severe and critical disease. This necessity further demonstrates the feasibility of the four prescriptions for the treatment of 2019-nCoV.

Pathway analysis

According to the KEGG enrichment analysis results of the potential targets, it can be inferred that the four prescriptions can achieve therapeutic effects against COVID-19 by targeting antiviral, inflammatory response, immune regulation, cell apoptosis, and other pathways. The signaling pathways mainly focus on three aspects: (1) Antivirus. Among the top 39 signaling pathways, 12 are related to antiviral, such as Coronavirus disease—COVID-19. (2) Regulation of the immune system. There are six pathways associated with immune regulation. The overactivation of the immune system leads to a cytokine storm, an essential step in transforming from mild to severe diseases. The four prescriptions may play a role in modulating immunity, avoiding or mitigating cytokine storms by acting on the T cell receptor signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th1, and Th2 cell differentiation, Chemokine signaling pathway, and Fc epsilon RI signaling pathway by interfering with a range of pathophysiological processes, including the recruitment, activation, and secretion of immune cells. (3) Inflammatory response. There are four signaling pathways involved in inflammation, including the IL-17 signaling pathway, Th17 cell differentiation, C-type lectin receptor signaling pathway, and TNF signaling pathway. To sum up, the four CPMs mainly treat COVID-19 through anti-virus, immune regulation, and anti-inflammatory. Twenty-two of the top 39 signaling pathways can be attributed to these three areas, as shown in Table 5. The specific mechanisms of action of the four CPMs on the Coronavirus disease—COVID-19 pathway are shown in Figure 12.

Conclusion

TCM is the strength and highlight of China’s COVID-19 prevention and control plan. In the fight against COVID-19, TCM has been involved in the prevention, treatment, and rehabilitation. TCM and Western medicine complement and cooperate, which makes an essential contribution to the comprehensive control of COVID-19. In this study, the possible common mechanism of the action of four classic CPMs in treating COVID-19 has been unearthed. Consequently, 101 common active ingredients and 233 common targets were screened out. There were 51 potential targets and 92 related pathways associated with COVID-19. Further analysis revealed that the active ingredients might be flavonoids, such as quercetin, luteolin, and acacetin. The enrichment analysis of 51 potential targets indicated that these targets could be applied to treat COVID-19 by activating broad spectrum antiviral, immune regulatory, and inflammatory responses through the regulation of the Coronavirus disease—COVID-19, cytokine-cytokine receptor interaction, IL-17 signaling pathway, and others. Due to intra-laboratory and multiple conditions limitations, this study explored the common mechanism of action of four PCMs for treating COVID-19 through network pharmacology and molecular dynamics with some limitations. In the future, we will further validate the candidate targets and...
potential signaling pathways predicted in this study by in vivo and in vitro experiments. China is willing to unite people from all countries to fight the epidemic and share the experience and achievements of Chinese medicine.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary material.

Author contributions

HY directed the research and revised the manuscript. LW and ZW performed the research and wrote the manuscript. XW modified the tables and figures and revised the manuscript. LY, JW, and YL revised the manuscript. All authors have read and approved the manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (81873263).

References

1. Cohen MS, Wohl DA, Fischer WA II, Smith DM, Eron JJ. Outpatient treatment of severe acute respiratory syndrome coronavirus 2 infection to prevent coronavirus disease 2019 progression. Clin Infect Dis. (2021) 73:1717–21. doi: 10.1093/cid/ciaa494
2. Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsieh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (Covid-19): the epidemic and the challenges. Int J Antimicrob Agents. (2020) 55:105924. doi: 10.1016/j.ijantimicag.2020.105924
3. Valent N, Britton GI, Gruber C, Hegde S, Kim J, Kuksin M, et al. Immunology of Covid-19: current state of the science. Immunity. (2020) 52:910–41. doi: 10.1016/j.immuni.2020.05.002
4. Dong M, Zhang J, Ma X, Tan J, Chen L, Liu S, et al. Ace2, Tmprss2 distribution and extrapulmonary organ injury in patients with Covid-19. Biomed Pharmacother. (2020) 113:110678. doi: 10.1016/j.biopha.2020.110678
5. Wang K, Chen W, Zhang Z, Deng Y, Lian J-Q, Du P, et al. Cd147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther. (2020) 5:1–10. doi: 10.1038/s41392-020-00426-x
6. Zhao Y-M, Shang Y-M, Song W-B, Li Q-Q, Xie H, Xu Q-F, et al. Follow-up study of the pulmonary function and related physiological characteristics of Covid-19 survivors three months after recovery. EClinicalMedicine. (2020) 25:100463. doi: 10.1016/j.eclinm.2020.100463
7. Luo H, Gao Y, Zou J, Zhang S, Chen H, Liu Q, et al. Reflections on treatment of Covid-19 with traditional Chinese medicine. Chin Med. (2020) 15:1–14. doi: 10.1186/s13020-020-00375-1
8. Hu K, Guan W-J, Bi Y, Zhang W, Li L, Zhang B, et al. Efficacy and safety of lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine. (2021) 85:153242.
9. Ling C, Fang L, Jinhui W, Yan SJ, Jinsen X, Bi S, et al. Clinical efficacy of Shufeng Jiedu capsule combined with western medicine in treatment of common Covid-19 patients by retrospective analysis. Chin J Exp Tradit Med Formul. (2020) 26:14–20.
10. Can D, Wenguang X, Chuanjuan Z, Guobing S, Zhengliang L, Qinglin L, et al. Clinical observation on Jinhua Qinggan granule combined with conventional western medicine therapy in treating mild cases of coronavirus. J Tradit Chin Med. (2020) 61:1473–7.
11. Wenguang X, Changqing A, Chuanjuan Z, Jixin Z, Min H, Yu W, et al. Clinical observation on 34 patients with novel coronavirus pneumonia (Covid-19) treated with integrated traditional Chinese and Western medicine. J Tradit Chin Med. (2020) 61:375–82.
12. Zhuzhu W, Fan Z, Chu Y, Wang H, Yang Y, Wu L, et al. Chinese patent medicines in the treatment of coronavirus disease 2019 (Covid-19) in China. Front Pharmacol. (2020) 11:1086. doi: 10.3389/fphar.2020.01086
13. Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinbai M, Yongxia S, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res. (2020) 156:104761. doi: 10.1016/j.phrs.2020.104761
14. Yanbay B, Yingjie G, Yujing S, Lei B, Rongmei Y, Xin M, et al. Study on broad-spectrum antiviral effect of Shufeng Jiedu capsules. J New Chin Med. (2019) 51:5–8.
15. Ji S, Bai Q, Wu X, Zhang D-W, Wang S, Shen J-L, et al. Unique synergistic antiviral effects of Shufeng Jiedu capsule and oseltamivir in influenza

Acknowledgments

We are thankful to Tianjin University of Traditional Chinese Medicine for the help in conducting this study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.874611/full#supplementary-material
16. Jing L, Li M, Jie L, Xiong X, Zhang S, et al. Study on the antipyretic mechanism of Shuifeng Jiedu pills. *Curr Protoc Herbs Drugs*. (2016) 47:2040–3.

17. Li M, Yan H, Yanbao H, Dongdong Z, Yanpeng Z, Jing L, et al. Study on mechanism for immunoregulation of Shuifeng Jiedu capsule. *Drug Eval Res*. (2019) 42:1763–8.

18. Zhi-peng H, Yuan-xue L, Lei H, Yu W, Yi H, Shui-ping Z, et al. Research progress on potential applications of Huoxtang Zhengqi in prevention and treatment of coronavirus disease 2019. *Dugs Clin*. (2020) 35:405–10.

19. Ling L, Ke W, Fang-guo L, Liang C, Bo Z, Shi-ying Z, et al. Effect of maxing Shigan decoction against type A influenza virus infection in mice induced by viral lung injury based on Tbr4-Mdyb-171a signal pathways. *Chin Tradit Herb Drugs*. (2017) 48:1591–6.

20. Ling L, Jia-Min W, Jian-Jun OY, Jue H, Can I, PIN Y, et al. Study on screening and mechanism of effective Chinese medicine for influenza virus pneumonia. *Chin J Immunol*. (2018) 34:1168–73.

21. da Hao C, Xiao PG. Network pharmacology: a rosetta stone for traditional Chinese medicine. *Drug Dev Res*. (2014) 75:299–312. doi: 10.1016/j/ddbr.21214.

22. Zhu B, Zhang W, Yang L, Hu S, Rui G, Sun Z, et al. Network pharmacology-based identification of protective mechanism of Panax notoginseng saponins on aspirin induced gastrointestinal injury. *Biomed Pharmacother*. (2018) 105:159–66. doi: 10.1016/j.biopha.2018.04.054.

23. Huang J, Fan C, Tan HY, Hong M, Zheng Q. Identification of the active compounds and significant pathways of Yinchenghuan decoction based on network pharmacology. *Med Mol Rep*. (2017) 16:4583–92. doi: 10.3892/mmr.2017.7149.

24. Liu H, Wang J, Zhou W, Wang Y, Jia J. Systems approaches and phytopharmacology for drug discovery from herbal medicines: an example using licorice. *J Ethnopharmacol*. (2013) 146:773–93. doi: 10.1016/j.jep.2013.02.004.

25. Xu X, Zhang W, Huang C, Li Y, Yu H, Wang Y, et al. A novel chemometric method for the prediction of human oral bioavailability. *Int J Mol Sci*. (2012) 13:6964–82. doi: 10.3390/ijms13060964.

26. Walters WP, Murcko MAJ. Prediction of ‘drug-likeness’. *Adv Drug Deliv Rev*. (2002) 54:255–71. doi: 10.1016/s0169-409x(02)00030-0.

27. Yoshihiro Y, Masaaki K, Minoru K, Susumu G. Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. *Bioinformatics*. (2010) 26:2454–6. doi: 10.1093/bioinformatics/btq176.

28. Mauri A, Consonni V, Pavan M, Todeschini R. Dragon software: an easy approach to molecular descriptor calculations. *Match*. (2016) 56:237–48.

29. Huang J, Tang H, Cao S, He Y, Feng Y, Wang K, et al. Molecular targets and associated potential pathways of Danshu capsules in hyperplasia of mammary glands based on systems pharmacology. *Evid Based Complement Alternat Med*. (2017) 2017:1933058. doi: 10.1155/2017/1933058.

30. Yang L, Liu W, Hu Z, Yang M, Li J, Fan X, et al. A systems pharmacology approach for identifying the multiple mechanisms of action of the Wei Pi Xiao decoction for the treatment of gastric precancerous lesions. *Evid Based Complement Alternat Med*. (2019) 2019:1562707. doi: 10.1155/2019/1562707.

31. Bardou P, Mariette J, Escudie P, Demiel C, Klopp C, Iennn: a free and open-source Venn diagram viewer. *BMC Bioinformatics*. (2014) 15:293. doi: 10.1186/1471-2105-15-293.

32. Piñero J, Queralt-Rosinach N, Bravo A, Deu-Pons J, Bauer-Mehren A, Baron A, et al. Disgenet: a discovery platform for the dynamic exploration of human diseases and their genes. *Database*. (2015) 2015:ba028. doi: 10.1093/database/bav028.

33. Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards suite, from gene data mining to disease genome sequence analyses. *Curr Protoc Bioinformatics*. (2016) 54:1:30–1. doi: 10.1002/9780470056090.ch1.

34. Feindt W, Oppenheim SJ, DeSalle R, Mehr S. Good citizenship made easy: a step-by-step guide to submitting RNA-Seq data to NCBI. *Curr Protoc Bioinformatics*. (2016) 86:6.7. doi: 10.1002/0471010970.ch1.

35. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The string database in 2017: quality-controlled protein-protein association networks, made broadly accessible. *Nucleic Acids Res*. (2016) 45:D626–8. doi: 10.1093/nat/gkw937.

36. Chen C-H, Chen S-H, Wu H-H, Ho C-W, Ko M-T, Lin C-Y. Cytohubba: identifying hub objects and sub-networks from complex interactome. *BMC Syst Biol*. (2014) 8:511. doi: 10.1186/1752-0509-8-S4-S11.

37. Ashburner M, Ball CA, Blake JA, Botstein D, Cherry JM, Gene ontology: tool for the unification of biology. *Nat Genet*. (2000) 25:25–9. doi: 10.1038/75556.

38. The Gene Ontology Consortium. Expansion of the gene ontology knowledgebase and resources. *Nucleic Acids Res*. (2017) 45:D331–8. doi: 10.1093/nar/gkw1198.
60. Gerin F, Sener U, Erman H, Yilmaz A, Aydin B, Armutcu F, et al. The effects of quercetin on acute lung injury and biomarkers of inflammation and oxidative stress in the rat model of sepsis. *Inflammation*. 2016 39:700-5. doi: 10.1007/s10753-015-0296-9

61. Li Y, Yao J, Han C, Yang J, Chaudhry MT, Wang S, et al. Quercetin, inflammation and immunity. *Nutrients*. (2016) 8:167. doi: 10.3390/nu8030167

62. Casas–Grajales S, Vázquez–Florez LF, Ramos–Tovar E, Hernández–García S, Flores–Beltrán BE, Cerda–García–Reyes CM, et al. Quercetin reverses experimental cirrhosis by immunomodulation of the proinflammatory and profibrotic processes. *Fundam Clin Pharmacol*. (2017) 31:610–24. doi: 10.1111/fcp.12315

63. Valentová K, Sima P, Rytková Z, Králatin J, Malachová K, Koen V. (Anti) mutagenic and immunomodulatory properties of quercetin glycosides. *J Sci Food Agric*. (2016) 96:1492-9. doi: 10.1002/jsfa.7251

64. Wu SN, Chang HT, Shen AY, Lo YK. Differential effects of quercetin, a natural polyphenolic flavonoid, on L–type calcium current in pituitary tumor (GH3) cells and neuronal NG108-15 cells. *J Cell Physiol*. (2003) 195:298-308. doi: 10.1002/jcp.10244

65. Wu CP, Calcagno AM, Hadiisky SB, Ambudkar SV, Barrand MA. Modulatory effects of plant phenols on human multidrug–resistance proteins 1, 4 and 5 (Abcc1, 4 and 5). *FEBS J*. (2005) 272:4725–40. doi: 10.1111/j.1742-4658.2005.04888.x

66. Thalakazhna SH, Rupasinghe HS. Flavonoid bioavailability and attempts for bioavailability enhancement. *Nutrients*. (2013) 5:3367-87. doi: 10.3390/nu5093367

67. Gutiérrez–Venegas G, Torras–Ceballos A, Gómez–Mora JA, Fernández–Rojas B. Luteolin, quercetin, genistin and quercetin conjugate inhibit the effects of lipopolysaccharide obtained from Porphyromonas gingivalis in H9c2 cardiomyoblasts. *Cell Mol Biol Lett*. (2017) 22:1–12. doi: 10.1186/s11658-017-0047-z

68. Tu D-G, Lin W-T, Yu C-C, Lee S-S, Peng C-Y, Lin T, et al. Chemotherapeutic effects of kaempferol in the osteo-sensitivity enhancement and interleukin-6/signal transducer and activator of transcription 3 signaling repression of oral cancer stem cells. *J Formos Med Assoc*. (2016) 115:1032-8. doi: 10.1016/j.jfma.2016.08.009

69. Abdallah HM, Esmat A. Antioxidant and Anti-inflammatory activities of the major phenolics from *Securigera securidaca*. *J Ethnopharmacol*. (2017) 205:1–6. doi: 10.1016/j.epsl.2017.04.022

70. Zhao Y, Xu Y, Li X, Jin Q, Sun J, Zhang J, et al. Synthesis, anti-HIV-1 activities of kaempferol and kaempferol-7-o-glucoside isolated from *Scutellaria baicalensis*. *Antiviral Res*. (2017) 146:112517. doi: 10.1016/j.antiviral.2021.106216

71. Behbahani M, Sayedipour S, Pourazar A, Shanehsazzadeh M. In vitro anti-HIV-1 activities of flavonoids against *Porphyromonas gingivalis* and *Staphylococcus aureus*. *Antiviral Res*. (2017) 134:539–72. doi: 10.1016/j.antiviral.2016.04.002

72. Miranda MT, Abreu CF, Loureiro AP, Souza-Filho ER, da Silva MM, et al. Luteolin, quercetin and biochanin A improve insulin resistance in obese mice. *Front Pharmacol*. (2017) 8:589. doi: 10.3389/fphar.2017.00589

73. Lyu S-Y, Rhim J-Y, Park W-B. Antiherpetic activities of flavonoids against *Herpes simplex virus* type 1 (HSV-1) and type 2 (HSV-2) in vitro. *Antiviral Res*. (2005) 68:36–42. doi: 10.1016/j.antiviral.2005.07.002

74. Wu SN, Chiang HT, Shen AY, Lo YK. Differential effects of quercetin, a natural polyphenolic flavonoid, on L–type calcium current in pituitary tumor (GH3) cells and neuronal Ng108-15 cells. *J Cell Physiol*. (2003) 195:298-308. doi: 10.1002/jcp.10244

75. Xu T, Ge X, Lu C, Dai W, Chen H, Xiao Z, et al. Baicalin attenuates ova-induced allergic airway inflammation through the inhibition of the NF-kB signaling pathway. *Aging*. (2011) 3:9310–27. doi: 10.18632/aging.102371

76. Zhao N, Dong Q, Fu X-X, Du L-L, Cheng X, Du Y-M, et al. Acacia blocks Kv1.3 channels and inhibits human T cell activation. *Cell Physiol Biochem*. (2014) 34:1359–72. doi: 10.11588/00366343

77. Cao R, Hu H, Li Y, Wang X, Xu M, Liu J, et al. Anti-SARS-CoV-2 potential of artemisinins in vitro. *ACS Infect Dis*. (2020) 6:2524–31.

78. Gilmore K, Zhou Y, Ramirez S, Pham IV, Fahmee U, Feng S, et al. In vitro efficacy of artemisinin-based treatments against SARS-CoV-2. *Sci Rep*. (2020) 11:1–14. doi: 10.1038/s41598-021-93361-y

79. Li G, Yuan M, Li H, Deng C, Wang Q, Tang Y, et al. Safety and efficacy of artemisinin-piperazine for treatment of COVID-19: an open label, non-randomised and controlled trial. *Int J Antimicrob Agents*. (2021) 57:106216. doi: 10.1016/j.ijantimicag.2020.106216

80. Lin Y, Wu F, Xie Z, Song X, Zhou Q, Wei I, et al. Clinical study of artemether in the treatment of coronavirus disease 2019. *Zhonghua Wei Zhong Bing Ji Jiu Yi Yi*. (2020) 32:417–20.

81. Uckun FM, Saund S, Windlass H, Tries J. Repurposing anti-malaria phenotype artemisinin as a Covid-19 drug. *Front Pharmacol*. (2021) 12:649532. doi: 10.3389/fphar.2021.649532

82. El Mazouri S, Aanniz T, Touhtoub I, Kandousi I, Hakmi B, Belaymani L, et al. Luteolin, quercetin and biochanin A: a promising mult-target therapeutic scaffold to treat COVID-19. *Int J Antimicrob Biol Sci*. (2021) 12:338–55. doi: 10.26502/ijabps.202104

83. Chang S-J, Huang S-H, Lin Y-J, Tsou Y-Y, Lin C-W. Overview of antiviral activity of rheum palmatum methanol extract and chrysophanol against Japanese encephalitis virus. *Arch Pharmacol*. (2014) 374:1117–23. doi: 10.1007/s00223-013-0325-x

84. Liu C-W, Tsai F-J, Tsai C-H, Lai C-C, Wan L, Ho T-Y, et al. Anti-Sars coronavirus 3c-like protease effects of isatsig indigotica root and plant-derived phenolic compounds. *Antiviral Res*. (2005) 68:36–42. doi: 10.1016/j.antiviral.2005.07.002

85. Rolta R, Yadav R, Sarala D, Trivedi S, Imran M, Sourirajan A, et al. In silico identification of potent FDA approved drugs against coronavirus Covid-19 main protease. *Chem Biol Lett*. (2021) 6:2524–31.

86. Gilmore K, Zhou Y, Ramirez S, Pham IV, Fahmee U, Feng S, et al. In vitro efficacy of artemisinin-based treatments against SARS-CoV-2. *Sci Rep*. (2020) 11:1–14. doi: 10.1038/s41598-021-93361-y

87. Bojadzic D, Alcazar O, Chen J, Chuang ST, Condor Capcha JM, Shehadeh L, et al. In silico identification of potent FDA approved drugs against coronavirus Covid-19 main protease: a drug repurposing approach. *Chem Biol Lett*. (2020) 202104

88. Hashemian SMR, Pourhanifeh MH, Hamblin MR, Shahzad MK, Mizraei H, Rdrp inhibitors and Covid-19: is molnupiravir a good option? *Biomed Pharmacother*. (2022) 146:112517. doi: 10.1016/j.biopha.2021.112517
Wang et al. 10.3389/fmed.2022.874611

99. Mirzaei M, Harismah K, Da’i M, Salarrezaei E, Roshandel Z. Screening efficacy of available HIV protease inhibitors on Covid-19 protease. J Med Med. (2020) 52:190–7.

100. Tian L, Qiang T, Liang C, Ren X, Jia M, Zhang J, et al. RNA-dependent RNA polymerase (RdRp) inhibitors: the current landscape and repurposing for the Covid-19 pandemic. Eur J Med Chem. (2021) 213:113201. doi: 10.1016/j.ejmech.2021.113201

101. Liu T, Luo S, Libby P, Shi GP. Cathepsin L-selective inhibitors: a potentially promising treatment for Covid-19 patients. Pharmacol Ther. (2020) 213:107587. doi: 10.1016/j.pharmthera.2020.107587

102. Zheng YY, Ma YT, Zhang JY, Xie X. Reply to: ‘Interaction between Raas inhibitors and Ace2 in the context of Covid-19’. Nat Rev Cardiol. (2020) 17:313–4. doi: 10.1038/s41591-020-0369-9

103. Sun ML, Yang JM, Sun YP, Su GH. [Inhibitors of Ras might be a good choice for the therapy of Covid-19 pneumonia]. Zhonghua Jie He Hu Xi Za Zhi. (2020) 43:219–22.

104. Chen CX, Wang JJ, Li H, Yuan LT, Gale RP, Liang Y. Jak-inhibitors for coronavirus disease-2019 (Covid-19): a meta-analysis. Leukemia. (2021) 35:2616–20.

105. Wu S, Jin Z, Peng C, Li D, Cheng Y, Zhu R, et al. Use of proton pump inhibitors are associated with higher mortality in hospitalized patients with Covid-19. J Glob Health. (2022) 12:05005. doi: 10.7189/jogh.12.05005

106. Choudhry N, Zhao X, Xu D, Zanin M, Chen W, Yang Z, et al. Chinese therapeutic strategy for fighting Covid-19 and potential small-molecule inhibitors against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). J Med Chem. (2020) 63:13205–27. doi: 10.1021/acs.jmedchem.0c00626

107. Li, LJCT, Drugs H. Effect of maxing shigan decoction against type A influenza virus infection in mice induced by viral lung injury based on Tlr4-Myd88-Traf6 signal pathways. Chin Tradit Herb Drugs. (2020) 51:11313–22.

108. Qi J, Qi X, Wang X. Clinical efficacy of different doses of Jinhuaqinggan granules on influenza and serum levels of cytokines. Mod Med. (2016) 44:1664–9.

109. Xia Y, Zhao Y, Wu YM, Huang KY, Shen F, Chen W, et al. Network-based pharmacology and bioinformatics study on the potential targets and mechanisms of “Jinhua Qingense granules” in the treatment of novel coronavirus pneumonia. Liangying J Tradit Chin Med. (2021) 48:18–23.222–3.

110. Gao, J, Xia J, Fan G, Zhang H, Zhu Y, Ming L. Clinical and pharmacological advances in the treatment of Covid-19 with the “three-drug triad”. Chin Sci Bull. (2022) 67:3296–10.

111. Lin J, Zhong W, Zeng G, Lin Q. Study on network pharmacology of Jinhua Qinggan granules in the treatment of novel coronavirus pneumonia. J Chin Med Mater. (2020) 43:2070–8.

112. Mao Y, Su Y, Xue P, Li L, Zhu S. Exploring the mechanism of action of Jinhua Qingxiang granules in the treatment of novel coronavirus pneumonia. J Chin Med Mater. (2020) 43:2842–8.

113. Zhang S, He GL, Lu F, Li L, Zhang B, Dai B, et al. Exploring the anti-influenza virus mechanism of Ma Heng Shu Gan Tang based on Thr/Philip- mediated Hn-A/B protein expression levels of ephedra first decoction. China J Tradit Chin Med Pharm. (2019) 34:1188–93.

114. Wang S, Wang W, Nan C, Wang X. Effects of silver forsythia on Jak/Stat signaling pathway and expression of Nif protein and Mxa protein in lung tissue of mice with Fm1-induced pneumonia. China Pharmacist. (2020) 23:213–7.

115. Du H, Wang P, Ma Q, Li N, Ding J, Sun TF, et al. A preliminary investigation on the effective components and mechanism of Hua Xiang Zheng Qi tang to inhibit the replication process of novel coronavirus. Modern Tradit Chin Med Mater Med World Sci Technol. (2020) 22:645–51.

116. Ren W, Liang P, Ma Y, Sun Q, Pu Q, Dong L, et al. Research progress of traditional Chinese medicine against Covid-19. Biomed Pharmacother. (2021) 137:111310. doi: 10.1016/j.biopha.2021.111310

117. Deng YJ. Study on active compounds from Huoxiang Zhengqi oral liquid for prevention of coronavirus disease 2019 (Covid-19) based on network pharmacology and molecular docking. Chin Tradit Herb Drugs. (2020) 51:1113–22.

118. Deng Y, Liu B, He Z, Liu T, Zheng R, Yang A, et al. Exploration of active compounds of Huoxiang Zhengqi oral liquid for the prevention of novel coronavirus pneumonia (Covid-19) based on network pharmacology and molecular docking method. Chin Tradit Herb Drugs. (2020) 51:1113–22.

119. Liu L, Xu Y, Jiang S, Xu Y. Exploring the possible mechanism of action of sparse wind relief capsules for the treatment of novel coronavirus pneumonia based on network pharmacology and molecular docking. Chin J Pharmacovigilance. (2021) 18:115–20.

120. Li K, Chen F, Li J, Chen X, Li M, He G. A network pharmacological study on the treatment of novel coronavirus pneumonia with Shu Feng Jie toxin capsule. J Chin Med Mater. (2020) 43:3080–7.

121. Liu J, Ma L, Liu J, Tian X, Xu J, Shen X, et al. Study on the mechanism of antipyretic effect of Shu Feng Jie toxin capsule. Chin Tradit Herb Drugs. (2016) 47:2040–3.

122. Ma L, Huang Y, Yanhao H, Zhang D, Zhang Y, Liu J, et al. Study on the mechanism of immunomodulatory effect of Shu Feng Jie toxin capsule. Drug Eval Res. (2019) 42:1763–8.

123. Loktionov A. Common gene polymorphisms and nutrition: emerging links with pathogenesis of multifactorial chronic diseases (review). J Nutr Biochem. (2003) 14:426–51. doi: 10.1016/S0955-2863(03)00032-9

124. Wang Y, Fan X, Qu H, Gao X, Cheng Y. Strategies and techniques for multi-component drug design from medicinal herbs and traditional Chinese medicine. Curr Top Med Chem. (2012) 12:1536–62. doi: 10.2174/156802612801391034

125. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. (2020) 395:507–13. doi: 10.1016/S0140-6736(20)30305-6

126. Zuma A, Hui DS, Arzhar EL, Memish ZA, Maeurer M. Reducing mortality from 2019 Ncov: host-directed therapies should be an option. Lancet. (2020) 395:e35–6. doi: 10.1016/S0140-6736(20)30305-6